Building a Science-Based Control Strategy Around CQAs and CPPs Building a Science-Based Control Strategy Around Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) In the ever-evolving landscape of regulatory affairs, a robust CMC (Chemistry, Manufacturing and Controls) control strategy is imperative for ensuring the quality, safety, and efficacy of pharmaceutical products. This article serves as a comprehensive guide for regulatory professionals, particularly those in the pharmaceutical and biotech industries, on how to construct an effective control strategy centered on Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). Context The regulatory frameworks in the US (FDA), EU (EMA), and…

How to define CQAs and CPPs using QbD principles and risk tools How to Define Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) Using QbD Principles and Risk Tools Regulatory Affairs Context In the pharmaceutical and biotech industries, establishing a robust Control Strategy is paramount for ensuring the consistent quality of products throughout their lifecycle. Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) form the core of this strategy, particularly when applying Quality by Design (QbD) principles. Understanding and defining CQAs and CPPs not only ensures compliance with regulatory expectations but also enhances the overall quality of the…

Translating development data into a commercial control strategy narrative Translating Development Data into a Commercial Control Strategy Narrative Regulatory Affairs Context The landscape of regulatory affairs (RA) within pharmaceutical and biotechnology industries continually evolves due to advancing scientific knowledge and changing regulations. A critical area of focus is the development and implementation of a Control Strategy (CS), which is essential for ensuring the quality of drug products throughout their lifecycle. This article covers the regulatory expectations and best practices for translating development data into a robust commercial control strategy narrative. Legal and Regulatory Basis In the US, the regulatory framework…

Control strategy expectations in Module 3 for FDA and EMA reviewers Control strategy expectations in Module 3 for FDA and EMA reviewers Regulatory Affairs Context In the pharmaceutical and biotech industries, the concept of control strategy is a critical component necessary for ensuring product quality and patient safety. Control strategies are integral in the development of pharmaceutical products, guiding decisions related to manufacturing processes, formulation, and quality assurance. Regulatory Affairs (RA) professionals must navigate the intricacies of control strategy formulation compliant with both FDA and EMA requirements. This article provides a comprehensive overview of the regulatory expectations for control strategies,…

Linking CQAs, CPPs and in process controls in a traceable framework Linking CQAs, CPPs and in process controls in a traceable framework This article serves as a regulatory explainer manual for Kharma and regulatory professionals focusing on the CMC lifecycle management with an emphasis on the control strategy involving Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). We will explore the regulatory expectations and guidelines applicable across the US, UK, and EU, providing a detailed overview of best practices and common deficiencies to avoid in regulatory submissions. Context In the pharmaceutical and biotechnology industries, the control strategy is a…

Using Risk Assessment to Select Critical Process Parameters for Control Using Risk Assessment to Select Critical Process Parameters for Control The selection and management of critical process parameters (CPPs) play a pivotal role in the development of a robust control strategy within the context of CMC lifecycle management. In the pharmaceutical and biotech industries, a scientifically sound approach based on risk assessment is essential to ensure the quality and consistency of drug products. This article serves as a regulatory explainer manual focused on utilizing risk assessment methodologies to inform the identification and selection of critical quality attributes (CQAs) and CPPs,…

Case studies of weak control strategies cited in health authority feedback Case studies of weak control strategies cited in health authority feedback In the pharmaceutical and biotech industries, the implementation of a robust Control Strategy is essential for ensuring the consistent quality of drug products. Regulatory Agencies, particularly in the US, UK, and EU, have issued guidelines that emphasize the importance of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) as pivotal components of Quality by Design (QbD). Misalignment in these areas can lead to significant deficiencies during regulatory review. This article presents an in-depth examination of regulatory expectations…

Aligning Control Strategy with PAT, RTRT, and CPV for Lifecycle Robustness Aligning Control Strategy with PAT, RTRT, and CPV for Lifecycle Robustness In the realm of pharmaceutical and biotech industries, ensuring the quality and efficacy of drug products through stringent regulatory frameworks is paramount. Central to this effort is the concept of the Control Strategy, which integrates Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs). This article aims to guide regulatory affairs professionals on aligning these concepts with Process Analytical Technology (PAT), Real-Time Release Testing (RTRT), and Continuous Process Verification (CPV) to enhance lifecycle robustness under the regulations of…

Control strategy for highly variable and complex biologics processes Control strategy for highly variable and complex biologics processes Regulatory Affairs Context The landscape of biopharmaceutical development is increasingly complex, particularly regarding the manufacturing of biologics. A robust control strategy that addresses critical quality attributes (CQAs) and critical process parameters (CPPs) is essential for ensuring product quality and regulatory compliance. The development and maintenance of a CMC (Chemistry, Manufacturing, and Controls) control strategy are crucial for the successful regulatory submission and approval process in various jurisdictions, including the US, EU, and UK. Legal/Regulatory Basis Regulatory frameworks governing biologics are predominantly outlined…

Tools and templates for visualising control strategy in CMC dossiers Tools and templates for visualising control strategy in CMC dossiers Regulatory Affairs Context The control strategy within the Chemistry, Manufacturing, and Controls (CMC) section of regulatory submissions is a fundamental component that ensures product quality throughout the lifecycle of pharmaceutical and biotech products. A well-defined control strategy delineates how critical quality attributes (CQAs) and critical process parameters (CPPs) will be monitored and controlled to ensure product consistency and compliance with regulatory requirements. This article seeks to provide a comprehensive overview of the tools and templates available for effectively visualising control…